Emerson Electric
EMR
$136.42
+1.13%
Emerson Electric Co. is a leading global provider of industrial automation solutions, operating within the Industrials sector and specializing in Industrial Machinery. The company has transformed from its origins as a fan manufacturer into a pure-play automation powerhouse, offering a wide range of automation software, hardware, and power tools through segments like Intelligent Devices and Software & Systems. The current investor narrative centers on the company's strategic pivot following the divestiture of its climate technology and consumer businesses, positioning it to capitalize on the long-term secular trend of factory automation, which promises to enhance productivity, uptime, and safety for its manufacturing clients.…
EMR
Emerson Electric
$136.42
Investment Opinion: Should I buy EMR Today?
Rating & Thesis: Hold. Emerson is a high-quality industrial automation leader undergoing a strategic transformation, but near-term growth deceleration and margin pressure create an unfavorable risk/reward profile at the current valuation, warranting a neutral stance until clearer signs of a reacceleration emerge.
Supporting Evidence: The recommendation is supported by four key data points. First, valuation is stretched on a trailing basis (P/E 32.20x, P/S 4.10x) but more reasonable forward (P/E 19.07x). Second, revenue growth has decelerated sharply to 4.07% YoY. Third, profitability is under pressure, with Q1 net income and gross margin down sequentially. Fourth, the stock exhibits weak momentum, down 8.21% over three months and underperforming the S&P 500 by over 16 percentage points during that period. The robust TTM FCF of $2.575B and solid balance sheet (D/E 0.678) provide a floor but do not offset the growth concerns.
Risks & Conditions: The two biggest risks are sustained revenue growth deceleration below 5% and further gross margin compression below 48%. This Hold rating would upgrade to a Buy if revenue growth reaccelerates above 8% YoY and gross margins stabilize above 50%, confirming the automation cycle remains intact. It would downgrade to a Sell if revenue growth turns negative or if the stock breaks decisively below its 52-week low of $114.91. Relative to its own history and sector peers, the stock is overvalued based on trailing earnings but fairly valued based on forward expectations, implying the market is pricing in a significant earnings recovery that is not yet evident in the reported numbers.
Sign up to view all
EMR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Emerson possesses strong long-term attributes: a leading market position, strategic focus, and excellent cash flow. However, these are currently overshadowed by concerning near-term signals: decelerating growth, compressing margins, weak price momentum, and a premium trailing valuation that demands a growth reacceleration to justify. The forward P/E offers some valuation support, but the stock likely treads water until growth reaccelerates or the multiple fully resets. The stance would upgrade to bullish on confirmation of sustained revenue growth above 6% and margin stabilization. It would turn bearish if the price breaks below $130 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $177.35 and implied upside of +30.0% versus the current price.
Average Target
$177.35
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$109 - $177
Analyst target range
Analyst coverage for Emerson is limited, with only 7 analysts providing estimates, which is low for a company of its market cap and suggests it may be under-followed relative to its peers, potentially leading to less efficient price discovery. The consensus sentiment, inferred from institutional ratings, appears mixed to slightly positive, with recent actions including an upgrade from UBS to 'Buy' and a downgrade from Deutsche Bank to 'Hold', while firms like Citigroup and Evercore ISI maintain 'Buy' or 'Outperform' ratings. A specific average target price and implied upside cannot be calculated from the provided data, as only EPS and revenue estimates are given without corresponding price targets, indicating insufficient data to quantify the street's price expectations and highlighting the need for investors to conduct independent valuation work.
Bulls vs Bears: EMR Investment Factors
The evidence is currently balanced but tilts bearish in the near term due to deteriorating momentum and fundamental metrics. The bull case rests on Emerson's strong strategic positioning, cash flow, and reasonable forward valuation. The bear case is driven by clear deceleration in revenue growth, margin compression, and a premium trailing multiple that is not supported by current growth rates. The single most important tension in the investment debate is whether the company's 4% revenue growth is a temporary pause or a sign of a more sustained slowdown in the automation cycle. The resolution of this growth question will determine if the stock can justify its premium valuation or faces further multiple compression.
Bullish
- Strong Free Cash Flow Generation: Emerson generates robust free cash flow, with TTM FCF of $2.575 billion. This provides ample internal funding for strategic investments, dividends, and share repurchases, supporting shareholder returns and financial flexibility.
- Strategic Pure-Play Automation Focus: Following divestitures, Emerson is now a pure-play industrial automation leader. This positions it to capitalize on the secular trend of factory automation, a long-term growth driver for manufacturing productivity and safety.
- Healthy Profitability Margins: The company maintains solid profitability with a trailing net margin of 12.73% and an operating margin of 19.60%. This operational efficiency provides a buffer against potential revenue headwinds.
- Conservative Balance Sheet: Emerson's debt-to-equity ratio of 0.678 indicates a conservatively managed capital structure. This low leverage reduces financial risk and provides capacity for strategic acquisitions or shareholder returns.
Bearish
- Significant Revenue Growth Deceleration: Q1 2026 revenue grew only 4.07% YoY, a sharp slowdown from prior quarters like Q4 2025. This deceleration raises concerns about the company's near-term growth trajectory in its core automation markets.
- Recent Earnings and Margin Pressure: Q1 2026 net income of $605 million declined from $637 million in Q4 2025. Gross margin compressed to 48.56% from 52.94% in the prior quarter, indicating cost pressures or unfavorable sales mix.
- Premium Trailing Valuation: The trailing P/E of 32.20x and P/S of 4.10x are at a premium to typical sector averages. This elevated valuation leaves the stock vulnerable to multiple compression if growth continues to disappoint.
- Weak Recent Price Momentum: The stock is down 4.45% over the past month and 8.21% over three months, underperforming the S&P 500 by wide margins. It trades near 27% of its 52-week range, indicating a breakdown in bullish momentum.
EMR Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 16.25% gain, but is currently experiencing a significant pullback from its highs. As of the latest close at $136.42, the price is trading at approximately 27% of its 52-week range, calculated from a low of $114.91 to a high of $165.15, indicating it is much closer to its annual lows than its highs and suggesting a potential value opportunity or a breakdown in momentum. Recent momentum has been sharply negative, with the stock down 4.45% over the past month and 8.21% over the past three months, a stark divergence from the positive yearly trend that signals a potential trend reversal or a deep correction within the broader uptrend. Key technical support is firmly established at the 52-week low of $114.91, while immediate resistance lies near the recent highs around $165.15; a sustained break below support would signal a bearish continuation, while reclaiming the $150 level could indicate a recovery. With a beta of 1.255, the stock is approximately 26% more volatile than the broader market (SPY), which is important for risk management as it implies larger swings, a characteristic underscored by its significant 23.74% maximum drawdown.
Beta
1.25
1.25x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$117-$165
Price range past year
Annual Return
+16.3%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | +4.4% |
| 3m | -8.2% | +9.3% |
| 6m | +6.4% | +10.5% |
| 1y | +16.3% | +28.8% |
| ytd | +0.4% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue growth is positive but has shown signs of deceleration; the most recent Q1 2026 revenue was $4.345 billion, representing a 4.07% year-over-year increase, yet this marks a slowdown from the stronger growth seen in prior quarters like Q4 2025's $4.855 billion. Segment data reveals the Intelligent Devices segment is the primary growth driver with $2.39 billion in revenue, significantly outpacing Software and Systems at $1.453 billion and Safety and Productivity at $503 million, indicating the core hardware business remains the dominant engine. The company is solidly profitable, with Q1 2026 net income of $605 million and a gross margin of 48.56%, though this gross margin has compressed from the 52.94% reported in the previous Q4, signaling potential cost pressures or sales mix shifts. Profitability metrics are healthy with a trailing net margin of 12.73% and an operating margin of 19.60%, but the quarterly net income of $605 million is down from $637 million in the prior quarter, suggesting near-term earnings pressure. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.678 and a current ratio of 0.876, indicating adequate but not excessive liquidity to meet short-term obligations. Cash generation is robust, with trailing twelve-month free cash flow of $2.575 billion, providing ample internal funding for growth initiatives, dividends, and share repurchases, as evidenced by the Q1 2026 operating cash flow of $699 million and a payout ratio of 51.98%.
Quarterly Revenue
$4.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.48%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 32.20x, while the forward PE is significantly lower at 19.07x, indicating the market expects a substantial recovery in earnings over the next twelve months, aligning with analyst EPS estimates averaging $9.16. Compared to sector averages implied by the provided data, Emerson's trailing PE of 32.20x and Price-to-Sales (PS) ratio of 4.10x suggest a premium valuation, which may be justified by its leading market position in industrial automation and its strategic transformation into a pure-play operator. Historically, the stock's own trailing PE has fluctuated significantly, with recent quarterly values ranging from 15.69x to 97.81x; the current 32.20x sits above the lower end of this range but well below the extreme highs, suggesting expectations are optimistic but not at peak historical levels, leaving room for multiple compression if growth disappoints.
PE
32.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson faces near-term financial risks from earnings pressure, as Q1 2026 net income declined 5% sequentially to $605 million. Gross margin compression from 52.94% to 48.56% quarter-over-quarter signals potential ongoing cost inflation or a shift to lower-margin products. Revenue concentration is a moderate risk, with the Intelligent Devices segment contributing 55% of total revenue ($2.39B of $4.345B in Q1), making overall performance highly dependent on this cyclical hardware business. The company's valuation depends on a growth reacceleration, as the high trailing P/E of 32.20x is unsustainable if the current 4% revenue growth rate persists.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a trailing P/E of 32.20x and P/S of 4.10x, Emerson carries a significant premium that could compress if investor sentiment shifts away from growth-oriented industrials or if sector multiples contract. The stock's beta of 1.255 indicates it is 26% more volatile than the market, amplifying downside during broader sell-offs, as evidenced by its 23.74% maximum drawdown. Competitive risks include potential disruption from newer software-centric automation players and pricing pressure in its core hardware markets, which could further pressure the recently declining margins.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current deceleration, where Q1's 4% revenue growth becomes the new norm, and margin compression persists due to competitive and cost pressures. This would lead to significant earnings misses versus the $9.16 forward EPS estimate, triggering multiple downgrades from the limited analyst pool. Combined with a broader market downturn amplified by the stock's high beta, this could drive the price down to retest its 52-week low of $114.91. From the current price of $136.42, this represents a realistic downside of approximately -16%. A more severe recessionary scenario in industrial end-markets could push the drawdown toward the historical maximum of -24%.
FAQ
The key risks, ranked by severity, are: 1) Growth Deceleration: Revenue growth slowed to 4.07% YoY, and if this becomes sustained, the premium valuation will collapse. 2) Margin Pressure: Gross margin compressed over 400 basis points QoQ to 48.56%, threatening profitability. 3) Valuation Compression: The high trailing P/E of 32.20x leaves the stock exposed to derating in a risk-off environment. 4) Cyclical Exposure: As an industrial machinery company with a beta of 1.255, EMR is highly sensitive to economic cycles and could underperform if industrial capex slows further.
The 12-month forecast for EMR is a range-bound outcome with a neutral bias. The base case (60% probability) sees the stock trading between $135 and $155, as muted growth and margin pressures offset its strong cash flow and balance sheet. The bull case (25% probability) targets $165 to $180, contingent on a reacceleration of revenue growth and margin recovery. The bear case (15% probability) warns of a drop to the $115 to $130 range if the industrial slowdown worsens. The most likely scenario is the base case, predicated on the assumption that the company meets forward EPS estimates but fails to reaccelerate growth meaningfully.
EMR's valuation is mixed. It is overvalued based on trailing earnings, with a P/E of 32.20x that is difficult to justify given the 4% revenue growth. However, it appears fairly valued to slightly undervalued based on forward expectations, with a forward P/E of 19.07x aligned with analyst EPS estimates of $9.16. This dichotomy means the market is pricing in a significant earnings recovery over the next year. If that recovery materializes, the stock is fairly valued. If growth remains stagnant, the current price is overvalued and vulnerable to multiple compression.
EMR is a good stock to buy for a specific type of investor: a long-term, patient investor who believes in the secular automation trend and is comfortable with near-term cyclical headwinds. The current valuation is reasonable on a forward basis (P/E 19.07x) given its quality, but the recent 4% revenue growth and margin compression present clear near-term risks. With 16% potential downside to its 52-week low, it offers a better risk/reward on significant pullbacks. For investors seeking high growth or immediate catalysts, it is not a good buy at this moment.
EMR is far more suitable for a long-term investment horizon of 3-5 years rather than short-term trading. Its thesis is based on a multi-year secular automation trend, and the company's strategic transformation will take time to fully yield results. The stock's high beta of 1.255 and recent weak momentum make it volatile and challenging for short-term traders. Furthermore, its 1.6% dividend yield and share repurchase program are geared toward long-term total return. Investors should be prepared to hold through cyclical downturns to capture the full value of its automation leadership.
